The progress of biologics in the rheumatic disease

Kawahito Yutaka

doi:10.14961/cra.28.97

<p> At present, clinical remission becomes the real treatment target of rheumatoid arthritis (RA) due to an appearance of the biologics, and life prognosis as well as a joint function has been improving. Furthermore, biologics for different target molecules in RA is developing for patients showing inadequate response to conventional biologics. On the other hand, development of biologics for other rheumatic diseases except RA is not enough. Because the organ failure with immunoreaction has a complexity that the organ is built by various cells, it is suggested that the control of the disease is difficult only by the inhibition of one target molecule. In systemic lupus erythematosus, B-cell related molecules is popular for development of biologics, but the effect is not so stronger than conventional immunosuppressive drug and steroid therapy even if the decrease of the antibody production and the improvement of the complement are observed. In Sjogren's syndrome, biologics is suggested to be effective for the extraglandular symptom, but to be difficult in improvement of the glandular symptom. In Japan rituximab is approved for ANCA-related vasculitis, molecules target for the surface marker of B lymphocyte for vasculitis have a lot of attention. Various preparations also are during a clinical trial about fibrosis of the scleroderma. The development of the biologics for other rheumatic diseases except RA is slow, but it will be pushed forward in future.</p>

The progress of biologics in the rheumatic disease

Bibliographic Information

Abstract

Journal

Keywords

Details 詳細情報について

Export

Report a problem